Multi-center analytical evaluation of a novel automated tacrolimus immunoassay

Shipkova, Maria;Vogeser, Michael;Ramos, Pedro Alía;Verstraete, Alain G.;Wallemacq, Pierre;et.al.
(2014) Clinical Biochemistry — Vol. 47, n° 12, p. 1069-1077 (2014)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 1.01 MB

Details

Authors
  • Shipkova, Maria
    Author
  • Vogeser, Michael
    Author
  • Ramos, Pedro Alía
    Author
  • Verstraete, Alain G.
    Author
  • Wallemacq, PierreUCLouvain
    Author
Show more
Abstract
Background: Tacrolimus (TAC) is a post-transplantation immunosuppressant drug used in patients for whom careful monitoring of TAC concentration is essential. A new semi-automated immunoassay for TAC measurement, the Elecsys Tacrolimus assay, is available and has been assessed in a multi-center evaluation. Methods: Residual whole blood samples from patients undergoing TAC therapy after organ transplant were used in assay evaluation at five clinical laboratories in Europe. Experiments included imprecision according to CLSI EP5-A2 (within-run and intermediate), functional sensitivity, linearity according to CLSI EP6-A, and recovery from external quality assessment scheme (EQAS) samples. The assay was compared to LC-MS/MS used routinely at each investigational site, and to the Abbott Architect immunoassay. Results: Linearity from 0.5 to 40. μg/L was observed and functional sensitivity of 0.3. μg/L (CV. ≤. 20%) was determined. Within-run imprecision was ≤ 5.1% on cobas e 602 (5.1% at 1.5 μg/L) and ≤ 8.9% (8.9% at 0.8 μg/L) on cobas e 411. The intermediate imprecision for TAC concentrations ≥. 6.8 μg/L was ≤ 6.5%. At lower therapeutic concentrations (to 1.5 μg/L) it was consistently ≤ 10%. Deming regression analysis of method comparison to LC-MS/MS yielded slopes of 1.07 (95%CI: 1.05/1.10) for heart transplant samples, 1.13 (95%CI: 1.09/1.16) for kidney, and 1.05 (95%CI: 1.02/1.08) for lung transplant samples. Conclusions: The Elecsys Tacrolimus assay has good linearity, functional sensitivity and intermediate imprecision and is comparable to LC-MS/MS methods. The over-all performance of ECLIA demonstrates a modern generation TAC assay that meets the demands of monitoring drug concentrations in current immunosuppressive regimens. © 2014.
Affiliations

Citations

Shipkova, M., Vogeser, M., Ramos, P. A., Verstraete, A. G., Orth, M., Schneider, C., & Wallemacq, P. (2014). Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. Clinical Biochemistry, 47(12), 1069-1077. https://doi.org/10.1016/j.clinbiochem.2014.03.023 (Original work published 2014)